What Makes Biogen (BIIB) an Attractive Long-Term Holding?
Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sivik Global Healthcare Krishen Sud | 15,000 | $2,750 | -25% | 2.09% |
| 2. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $195.04 | 3 | $585.11 | 19,611 | 2026-02-12 | Filing | |
| $122.72 | 1,235 | $151,559.20 | 27,842 | 2025-05-02 | Filing | |
| $222.54 | 455 | $101,255.70 | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | $239,766.00 | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | $748,046.74 | 34,810 | 2020-11-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $199.83 | 2,660 | $531,547.80 | 8,043 | 2026-02-09 | Filing | |
| $179.30 | 748 | $134,116.40 | 6,271 | 2026-02-02 | Filing | |
| $133.55 | 517 | $69,045.35 | 5,772 | 2025-09-02 | Filing | |
| $135.00 | 2,223 | $300,105.00 | 6,330 | 2025-07-08 | Filing | |
| $126.25 | 3,806 | $480,507.50 | 5,427 | 2025-05-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 571,571 | $104,786,111 | 1.11% | |
| 2. | 66,061 | $12,110,963 | 0.09% | |
| 3. | 50,923 | $9,335,714 | 0.1% | |
| 4. | 39,969 | $7,327,517 | 0.05% | |
| 5. | 62,530 | $6,653,428 | 0.01% |
News See All
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why
Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Biogen Inc. (NASDAQ:BIIB) Q4 2025 Earnings Call Transcript
Ruth: Please stand by. Morning. My name is Ruth, and I will be your conference operator today.
Here's What Analysts Think About Biogen Inc. (BIIB)
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8.
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress
On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, citing concerns that BIIB’s reliance on royalty streams and challenges in its core...
9 Most Undervalued Pharma Stocks to Buy Right Now
The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.
Biogen Inc. (NASDAQ:BIIB) Q3 2025 Earnings Call Transcript
Operator: Good morning. My name is Cynthia, and I will be your conference operator today.
Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT
Jefferies began covering Biogen Inc. (NASDAQ:BIIB) on September 26 with a Buy rating and a price target of $190.
Hedge Fund Resource Center